Biocon Limited (BIOCON) announced that its Pertuzumab biosimilar secured EMA CHMP approval, marking a significant milestone in expanding access to HER2-posit.
Biocon Limited (BIOCON) secures a 10-year supply contract for Pertuzumab in Brazil, marking a significant milestone in advancing HER2-positive breast cancer.
Biocon Limited (BIOCON) reports Q1 FY27 results with a 9% revenue increase, driven by strong biosimilars performance.
Biocon Limited (BIOCON) reports a 9% rise in total income to Rs 4,391 Cr for Q1 FY27, driven by strong Biopharma growth.
Biocon Limited (BIOCON) announces the U.S. launch of Yesafili™, a biosimilar to Regeneron’s Eylea® 2 mg, expanding access to eye treatment.
Biocon Limited (NSE: BIOCON) stock moves up 5% intraday to ₹435.0, testing resistance in the healthcare & biotechnology sector.
Biocon Limited (BIOCON) publishes pivotal clinical data supporting the effectiveness of Yesafili™, a biosimilar to Eylea®.
